Opinion|Videos|June 25, 2024
Non-adjuvant RSV Vaccine in Older Adults
Author(s)Carrie Koenigsfeld, PharmD, FAPhA
An RSV medical expert provides an overview of the RENOIR trial, which investigated the efficacy and safety of an adjuvanted RSV vaccine in adults aged 60 years and older, focusing on the vaccine's effectiveness in preventing RSV-associated lower respiratory tract infections and presenting other crucial findings from the study.
Advertisement
Episodes in this series
- The
RENOIR trial studied the safety and efficacy of non-adjuvanted vaccine in adults aged 60 years or older. What interim results were significant from this trial leading to the indication of the vaccine for this population?- Efficacy at preventing RSV-associated lower respiratory tract infections
- Adverse effects
- Trial limitations
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Beyond Cost Avoidance: Advancing Unit-Level Pharmaceutical Economics in Health Systems
2
Pharmacist Care Gets BP Patients to Goal Faster, Safer
3
Ivonescimab Significantly Extends OS Over Pembrolizumab in PD-L1-Positive Advanced NSCLC
4
Predictive Models Could Address Missing Data in Advanced Prostate Cancer
5